The Benefits of Stem Cell Therapy for Heart Disease

Results in a number of clinical trials using mesenchymal cells Mesenchymal stem cells are rare cells mainly found in the bone marrow or in adipose (fat) tissue that can give rise to a large number of tissue types such as bone, cartilage (the lining of joints), fat tissue and connective tissue (tissue that is in between organs and structures in the body). have demonstrated important improvements in quality of life. Patients receiving adult stems cells for heart disease experienced benefits including:

• An increase in quality of life
• Reduced anginaChest pain that occurs when diseased blood vessels restrict blood flow to the heart.
• Reduced re-hospitalizations
• Reduced Major Adverse Cardiac and Cerebral Events (MACCE)

The PRECISE Trial Showed Measurable Improvements in Oxygen Consumption and Physical Strength

The Okyanos treatment protocol is based upon the PRECISE trial, which demonstrated statistically significant improvements in:

• Oxygen consumption (mVO2mVO2 or maximum volume of oxygen consumed – the maximum amount of oxygen that a person can use. This is the best predictor of cardiac-related mortality.)
• Physical strength (MET scoreMET Score of METS represents metabolic equivalents – a way to measure physical strength and a strong predictor of adverse cardiac-related events.)
• Reduction in infarct size (wound size)

Safety and Adverse Complications

There were no liposuction or ADRCAdipose derived stem and regenerative cells injection-related MACCE (Major Adverse Cardiac and Cerebrovascular events) at either 6 or 18 months.

The PRECISE trial using stem cells for heart disease treatment was a multi-center, double-blinded placebo control study for end-stage patients with coronary artery diseaseHeart disease caused by plaque having built up in the arteries..

References

Adipose-Derived Regenerative Cells Improve Cardiac Functional Capacity at 18 Months in Chronic Ischemic Heart Disease Patients; Statistically Significant Improvement in MVO2 Reported at American Heart Association (2010, November 15) in Marketwire. Retrieved March 9, 2012, from http://www.marketwire.com/press-release/Adipose-Derived-Regenerative-Cells-Improve-Cardiac-Functional-Capacity-18-Months-Chronic-NASDAQ-CYTX-1353581.htm.